Skip to main content

Table 2 HTE reporting by study characteristics (n = 319 RCTs in 303 articles)

From: Dealing with heterogeneity of treatment effects: is the literature up to the challenge?

Characteristic N No. (%) Reporting HTE No. (%) Reporting Either subgroup or HTE
Journal of publication  
   Annals 30 11 (37) 16 (53)
   BMJ 47 9 (19) 18 (38)
   JAMA 50 21 (42) 33 (66)
   Lancet 101 21 (21) 53 (53)
   NEJM 91 30 (33) 60 (66)
Year of publication    
   1994 91 20 (22) 47 (52)
   1999 106 30 (28) 62 (58)
   2004 122 42 (34) 71 (58)
Medical condition under study   
   Cardiovascular 74 21 (28) 43 (58)
   Infectious disease 70 25 (36) 48 (69)
   Cancer 42 15 (36) 30 (71)
   Psychiatry/Neurology 25 7 (28) 12 (48)
   Other 108 24 (22) 47 (44)
First author's study region  
   North America 121 47 (39) 80 (66)
   Other 198 45 (23) 100 (51)
Study design   
   Parallel 304 89 (29) 177 (58)
   Crossover 15 3 (20) 3 (20)
Sample size   ** **
   Quintile 1 (median = 37) 64 9 (14) 18 (28)
   Quintile 2 (median = 124) 64 7 (11) 29 (45)
   Quintile 3 (median = 263) 64 22 (34) 45 (70)
   Quintile 4 (median = 549) 64 21 (33) 40 (63)
   Quintile 5 (median = 1560) 63 33 (52) 48 (76)
  1. Abbreviations: HTE, heterogeneity of treatment effects; RCTs, randomized controlled trials; BMJ, British Medical Journal; JAMA, Journal of the American Medical Association; NEJM, New England Journal of Medicine.
  2. p < 0.05 by Pearson Chi-square test
  3. p < 0.01 by Pearson Chi-square test
  4. §p < 0.05 by Fisher's exact test
  5. p < 0.01 by Fisher's exact test
  6. p < 0.05 by Mantel-Hantzel test for trend
  7. **p < 0.0001 by Mantel-Hantzel test for trend